SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 Against Mucormycosis At 11th Advances Against Aspergillosis and Mucormycosis Conference
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
- In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis
- Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies